Author

D. H. Peng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

A. Hata· 1 shared A. Lopez· 1 shared A. Padhye· 1 shared A. Viale· 1 shared A. Yousef· 1 shared B. L. Rodriguez· 1 shared B. Neel· 1 shared C. A. Class· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Hata

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

KRAS inhibition activates an actionable CD24 do-not-eat-me signal in pancreatic cancer

Y. Wei, M. Liu, E.-Y. Yen, J. Yao, Z. Xun, P. T. Nguyen, X. Wang, Z. Yang, A. Yousef, D. Pan, Y. Jin, C.-F. Li, M. S. Theardy, J. Park, Y. Cai, , H. Ying

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.

bioRxiv · Sep 21, 2023Cancer Biology

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer

J. Deng, D. H. Peng, D. Fenyo, Y. Hao, A. Lopez, D. Levin, M. Meynardie, M. Quinteros, M. Ranieri, S. Sahu, S. Lau, E. Shum, V. Velcheti, S. R. Punekar, N. Rekhtman, , K.-K. Wong

The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.

bioRxiv · Apr 18, 2023 · PreprintCancer Biology

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

D. H. Peng, B. L. Rodriguez, L. Diao, P. O. Gaudreau, A. Padhye, J. K. Ochieng, C. A. Class, J. J. Fradette, L. A. Gibson, L. Chen, J. Wang, L. A. Byers, D. L. Gibbons

This study shows that Th17 cells contribute to resistance to MEK inhibitor and anti-PD-L1 therapy in KRAS/p53 mutant lung cancers and suggests a triple combinatorial therapy to overcome resistance.

bioRxiv · Jun 7, 2020Cancer Biology